|  |  | 

India Top Headlines

Government Bans Remdesivir Exports Until Covid Situation in India Improves | India News


NEW DELHI: Following growing demand for Remdesivir for the treatment of Covid-19 amid an increase in severe cases, the Center has banned exports of Remdesivir injection and Remdesivir active pharmaceutical ingredients (API) until that improves the situation of Covid-19 in the country.
In addition, companies have been asked to increase production of the drug and all local manufacturers of Remdesivir have been advised to display details of their stockists or distributors on their website to facilitate access to the drug.
Drug inspectors and other officials have also been ordered to check stocks and verify their malpractices and also take other effective actions to curb hoarding and black marketing.
Used to treat Ebola, the antiviral drug has proven useful in treating Covid-19 patients.
Currently, seven Indian companies are producing Injection Remdesivir under a voluntary license agreement with the pharmaceutical company Americal Gilead Sciences which holds the patent for the product.
While the companies have an installed capacity of around 38.80 lakh units per month, the Department of Pharmaceutical Products is in discussions with the industry to assess the expansion of production capacity at the existing facilities.
Many cities in India witnessed a severe shortage of Remdesivir. The shortage also gave way to black marketing.
The Center has also recommended that states follow the National Clinical Management Protocol for COVID-19 that is evidence-based and includes Remdesivir as an investigational therapy, that is, where informed and shared decision-making is essential, in addition to making note the contraindications mentioned in the guidelines.
“The states and UT were informed that these steps should be communicated again to all hospitals, both in the public and private sectors, and compliance should be monitored,” said the Ministry of Health.

Original source